Procedural Outcomes of Percutaneous PDA Closure: Comparative Study Between Different Devices.
Primary Purpose
Congenital Heart Disease
Status
Unknown status
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Percutaneous PDA closure
Sponsored by
About this trial
This is an interventional treatment trial for Congenital Heart Disease
Eligibility Criteria
Inclusion Criteria:
- all patients who are candidate for transcatheter PDA closure
Exclusion Criteria:
- Patients with PDA dependent pulmonary circulation.
- Patients with small sized PDA which is silent by auscultation
- Patients with large sized PDA which is unsuitable for Trans-catheter closure
- Patients with PDA and severe irreversible pulmonary hypertension (Eisenmenger's syndrome) (7).
- Patients with active infection or active infective endarteritis.
- Patients refusing the study.
Sites / Locations
Outcomes
Primary Outcome Measures
Procedural safety
studying the occurrence of catheter related complications including
Occurrence of vascular access hematoma(Yes/No )
Occurrence of contrast induced nephropathy (Yes/No)
PDA closure Device embolization (Yes/No)
Cardiac tamponade (Yes/No)
Procedural efficacy
timing of complete closure of the PDA with no residual shunts
Residual left to right shunt (Yes/No)
Degree of the residual shunt (Trace, Mild , Moderate, severe)
Timing of closure of the shunt( immediately postprocedural, 24 hours post procedural , 1 month post procedural )
Procedural outcomes
comparison of echocardiography data that will be done pre catheter closure, one day post procedure and one month later ( left ventricular and atrial dimensions-left ventricular ejection fraction-pulmonary artery systolic pressure- degree of tricuspid regurge)
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT04303793
Brief Title
Procedural Outcomes of Percutaneous PDA Closure: Comparative Study Between Different Devices.
Official Title
Procedural Outcomes of Percutaneous PDA Closure: Comparative Study Between Different Devices.
Study Type
Interventional
2. Study Status
Record Verification Date
March 2020
Overall Recruitment Status
Unknown status
Study Start Date
June 1, 2020 (Anticipated)
Primary Completion Date
May 1, 2022 (Anticipated)
Study Completion Date
June 2022 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Assiut University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
To compare safety, efficacy and procedural outcome of percutaneous PDA closure using different approaches for better characterization of device selection criteria.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Congenital Heart Disease
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
100 (Anticipated)
8. Arms, Groups, and Interventions
Intervention Type
Device
Intervention Name(s)
Percutaneous PDA closure
Intervention Description
transcatheter patent ductus arteriosus closure
Primary Outcome Measure Information:
Title
Procedural safety
Description
studying the occurrence of catheter related complications including
Occurrence of vascular access hematoma(Yes/No )
Occurrence of contrast induced nephropathy (Yes/No)
PDA closure Device embolization (Yes/No)
Cardiac tamponade (Yes/No)
Time Frame
one month
Title
Procedural efficacy
Description
timing of complete closure of the PDA with no residual shunts
Residual left to right shunt (Yes/No)
Degree of the residual shunt (Trace, Mild , Moderate, severe)
Timing of closure of the shunt( immediately postprocedural, 24 hours post procedural , 1 month post procedural )
Time Frame
one month
Title
Procedural outcomes
Description
comparison of echocardiography data that will be done pre catheter closure, one day post procedure and one month later ( left ventricular and atrial dimensions-left ventricular ejection fraction-pulmonary artery systolic pressure- degree of tricuspid regurge)
Time Frame
one month
10. Eligibility
Sex
All
Minimum Age & Unit of Time
1 Month
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
all patients who are candidate for transcatheter PDA closure
Exclusion Criteria:
Patients with PDA dependent pulmonary circulation.
Patients with small sized PDA which is silent by auscultation
Patients with large sized PDA which is unsuitable for Trans-catheter closure
Patients with PDA and severe irreversible pulmonary hypertension (Eisenmenger's syndrome) (7).
Patients with active infection or active infective endarteritis.
Patients refusing the study.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Ahmed Mohamed Moheb El-Din
Phone
01060964666
Email
ahmedmoheb34567@gmail.com
12. IPD Sharing Statement
Learn more about this trial
Procedural Outcomes of Percutaneous PDA Closure: Comparative Study Between Different Devices.
We'll reach out to this number within 24 hrs